Abstract
Even though malnutrition is associated with an adverse prognosis after allogeneic stem cell transplantation, few studies have addressed the question what is the optimal nutritional support for these patients. There is a general agreement that the body weight, body mass index and nutritional intake can be used to guide the post-transplant nutritional support; enteral nutrition may then be tried but most patients will require parenteral nutrition. There is no scientific basis for further standardization of post-transplant nutritional support. The nutritional status with regard to amino acid as well as fatty acid metabolism and vitamin levels are important for immunoregulation. Several amino acids and their metabolites function as signaling molecules through their binding to specific receptors, and they are thereby become important both in dendritic cell differentiation and T cell activation and the metabolic switch that often occurs during the activation of immunocompetent cells. We review previous studies of nutritional support in allotransplant recipients and discuss possible molecular mechanisms involved in metabolic immunoregulation and the development of post-transplant immunemediated complications.
Keywords: Allogeneic, Stem cell transplantation, graft versus host disease, T cells, dendritic cells, metabolism, nutrition.
Current Pharmaceutical Biotechnology
Title:Nutrition in Allogeneic Stem Cell Transplantion - Clinical Guidelines and Immunobiological Aspects
Volume: 17 Issue: 1
Author(s): Tor H.A. Tvedt, Håkon Reikvam and Øystein Bruserud
Affiliation:
Keywords: Allogeneic, Stem cell transplantation, graft versus host disease, T cells, dendritic cells, metabolism, nutrition.
Abstract: Even though malnutrition is associated with an adverse prognosis after allogeneic stem cell transplantation, few studies have addressed the question what is the optimal nutritional support for these patients. There is a general agreement that the body weight, body mass index and nutritional intake can be used to guide the post-transplant nutritional support; enteral nutrition may then be tried but most patients will require parenteral nutrition. There is no scientific basis for further standardization of post-transplant nutritional support. The nutritional status with regard to amino acid as well as fatty acid metabolism and vitamin levels are important for immunoregulation. Several amino acids and their metabolites function as signaling molecules through their binding to specific receptors, and they are thereby become important both in dendritic cell differentiation and T cell activation and the metabolic switch that often occurs during the activation of immunocompetent cells. We review previous studies of nutritional support in allotransplant recipients and discuss possible molecular mechanisms involved in metabolic immunoregulation and the development of post-transplant immunemediated complications.
Export Options
About this article
Cite this article as:
Tvedt H.A. Tor, Reikvam Håkon and Bruserud Øystein, Nutrition in Allogeneic Stem Cell Transplantion - Clinical Guidelines and Immunobiological Aspects, Current Pharmaceutical Biotechnology 2016; 17(1) . https://dx.doi.org/10.2174/138920101701151027163600
DOI https://dx.doi.org/10.2174/138920101701151027163600 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS
Infectious Disorders - Drug Targets Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones
Anti-Cancer Agents in Medicinal Chemistry State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry N-glycomic Analysis of Z(IgA1) Partitioned Serum and Salivary Immunoglobulin A by Capillary Electrophoresis
Current Molecular Medicine Bacterial Contamination of Platelets and Septic Transfusions: Review of the Literature and Discussion on Recent Patents About Biofilm Treatment
Recent Patents on Anti-Infective Drug Discovery Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design